Daily15d
Novartis' Ribociclib named as Category 1 Preferred Adjuvant Treatment for Breast Cancer in NCCN Guidelines
Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4 ...
Pharmabiz16d
Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines
This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...
Zonebourse17d
Novartis : annonce la recommandation du ribociclib
Maeve Waldron-Lynch rejoint Tango Therapeutics, Inc. en tant que Senior Vice President, responsable du développement clinique 06/11 CI Bourse Zurich: toujours dans le vert, après la victoire ...
Trading Sat17d
Novartis : Annonce la recommandation du ribociclib
(CercleFinance.com) - Le ribociclib (Kisqali®) de Novartis est reconnu comme traitement adjuvant privilégié de catégorie 1 pour le cancer du sein par les directives de pratique clinique en ...
Novartis24d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...